Pliva opens new US$100m oral solid forms facility in Zagreb

Published: 25-Oct-2013

Raises annual capacity for Pliva and Teva by 25%

Pliva, a Croatian pharmaceutical manufacturer and a member of the Teva Group, has increased its production capacity for tablets and capsules by opening a new US$100m oral solid forms facility in Zagreb.

The investment also covers the transfer of the existing pilot plant for tablets to the new facility and a considerable increase of production capacities for sterile forms. Innovative technologies and cutting-edge and state-of-the-art equipment has been installed at the plant.

The opening took place in the presence of Zoran Milanović, Prime Minister of Croatia, Branko Grčić, Deputy Prime Minister and Minister of Regional Development and EU Funds, and Ivan Vrdoljak, Minister of Economy.

'This year has been especially important for us – we are about to complete one of the largest investment cycles in the company's history,' said Tihomir Orešković, President of Pliva's Management Board. 'I am glad that Teva is today one of the biggest private investors in Croatia and that its investments in the production facilities in Zagreb and Savski Marof total more than $200m.

'In addition to production and exports growth, this investment is important because it opens new jobs. Furthermore, every new job at Pliva multiplies a number of new jobs at the suppliers participating in Pliva's production chain.'

He added: 'I would like to use this opportunity and say that we are glad that an additional $20m investment in sterile forms has been also approved.'

The new oral solid forms facility raises Pliva's and Teva's annual capacity by two billion tablets (more than 25%). Medicinal products manufactured in the new production facility are mainly intended for EU and US markets, and commercial production will start as soon as the facility is approved by the FDA and other regulatory agencies.

You may also like